(RO) Roche Holding - Ratings and Ratios
Pharmaceuticals, Diagnostics, Digital Health, Cancer Treatments, Autoimmune
Description: RO Roche Holding
Roche Holding AG is a multinational healthcare company operating in the pharmaceuticals and diagnostics sectors globally, with a presence in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The companys pharmaceutical division focuses on various therapeutic areas, including oncology, hematology, and immunology, among others, offering treatments for a range of diseases.
The diagnostics division provides a broad portfolio of in vitro diagnostic tests and instruments for detecting and managing diseases such as cancer, diabetes, and infectious diseases. Roche also invests in digital health solutions, aiming to enhance patient care and disease management through innovative technologies.
From a financial perspective, Roche has a significant market presence with a market capitalization of approximately CHF 208.75 billion. The companys return on equity (RoE) stands at 67.87%, indicating a strong ability to generate profits from shareholder equity. The forward price-to-earnings (P/E) ratio is 14.18, suggesting that the companys future earnings growth is anticipated, potentially making it an attractive investment opportunity for those looking for growth in the pharmaceutical sector.
Key performance indicators (KPIs) such as revenue growth, R&D expenditure as a percentage of sales, and the number of new drug approvals or diagnostic solutions launched annually could provide further insights into Roches operational efficiency and innovation pipeline. For instance, a high R&D expenditure as a percentage of sales (typically around 10-20% for pharmaceutical companies) could indicate a strong commitment to innovation. Additionally, metrics like the debt-to-equity ratio and operating margin can offer insights into the companys financial health and operational profitability.
Roches diversified portfolio across pharmaceuticals and diagnostics, along with its commitment to R&D, positions it as a significant player in the global healthcare industry. Investors and analysts often closely monitor the companys pipeline of new treatments and diagnostic tools, as well as its financial performance, to gauge its future prospects.
RO Stock Overview
| Market Cap in USD | 260,914m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
RO Stock Ratings
| Growth Rating | -8.87% |
| Fundamental | 83.1% |
| Dividend Rating | 57.3% |
| Return 12m vs S&P 500 | -20.3% |
| Analyst Rating | - |
RO Dividends
| Dividend Yield 12m | 3.50% |
| Yield on Cost 5y | 3.58% |
| Annual Growth 5y | 1.30% |
| Payout Consistency | 100.0% |
| Payout Ratio | 82.6% |
RO Growth Ratios
| Growth Correlation 3m | -74.5% |
| Growth Correlation 12m | -16.4% |
| Growth Correlation 5y | -35.9% |
| CAGR 5y | 0.39% |
| CAGR/Max DD 5y | 0.01 |
| Sharpe Ratio 12m | 1.40 |
| Alpha | -15.30 |
| Beta | 0.307 |
| Volatility | 20.75% |
| Current Volume | 21.1k |
| Average Volume 20d | 21.6k |
| Stop Loss | 267.7 (-3%) |
| Signal | 0.43 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (20.05b TTM) > 0 and > 6% of Revenue (6% = 7.28b TTM) |
| FCFTA 0.22 (>2.0%) and ΔFCFTA 3.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 6.70% (prev 5.17%; Δ 1.52pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.37 (>3.0%) and CFO 34.60b > Net Income 20.05b (YES >=105%, WARN >=100%) |
| Net Debt (29.38b) to EBITDA (23.58b) ratio: 1.25 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (796.3m) change vs 12m ago -0.96% (target <= -2.0% for YES) |
| Gross Margin 73.66% (prev 72.93%; Δ 0.73pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 135.4% (prev 109.2%; Δ 26.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 11.03 (EBITDA TTM 23.58b / Interest Expense TTM 1.67b) >= 6 (WARN >= 3) |
Altman Z'' 4.11
| (A) 0.09 = (Total Current Assets 35.70b - Total Current Liabilities 27.58b) / Total Assets 94.77b |
| (B) 0.45 = Retained Earnings (Balance) 42.98b / Total Assets 94.77b |
| (C) 0.21 = EBIT TTM 18.43b / Avg Total Assets 89.57b |
| (D) 0.65 = Book Value of Equity 43.09b / Total Liabilities 66.09b |
| Total Rating: 4.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.10
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 9.18% = 4.59 |
| 3. FCF Margin 17.56% = 4.39 |
| 4. Debt/Equity 1.06 = 1.97 |
| 5. Debt/Ebitda 1.29 = 1.32 |
| 6. ROIC - WACC 16.43% = 12.50 |
| 7. RoE 67.56% = 2.50 |
| 8. Rev. Trend 16.08% = 0.80 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend -19.09% = -0.48 |
| 11. EPS CAGR 63.34% = 2.50 |
What is the price of RO shares?
Over the past week, the price has changed by +0.58%, over one month by +0.00%, over three months by -0.36% and over the past year by -6.26%.
Is Roche Holding a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RO is around 259.99 CHF . This means that RO is currently overvalued and has a potential downside of -5.8%.
Is RO a buy, sell or hold?
What are the forecasts/targets for the RO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 360 | 30.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 284.6 | 3.1% |
RO Fundamental Data Overview
Market Cap CHF = 209.18b (209.18b CHF * 1.0 CHF.CHF)
CCE Cash And Equivalents = 7.55b CHF (last quarter)
P/E Trailing = 23.2511
P/E Forward = 13.5135
P/S = 3.2948
P/B = 7.625
P/EG = 0.7112
Beta = 0.174
Revenue TTM = 121.28b CHF
EBIT TTM = 18.43b CHF
EBITDA TTM = 23.58b CHF
Long Term Debt = 26.46b CHF (from longTermDebt, last quarter)
Short Term Debt = 3.93b CHF (from shortTermDebt, last quarter)
Debt = 30.39b CHF (Calculated: Short Term 3.93b + Long Term 26.46b)
Net Debt = 29.38b CHF (from netDebt column, last fiscal year)
Enterprise Value = 232.02b CHF (209.18b + Debt 30.39b - CCE 7.55b)
Interest Coverage Ratio = 11.03 (Ebit TTM 18.43b / Interest Expense TTM 1.67b)
FCF Yield = 9.18% (FCF TTM 21.30b / Enterprise Value 232.02b)
FCF Margin = 17.56% (FCF TTM 21.30b / Revenue TTM 121.28b)
Net Margin = 16.53% (Net Income TTM 20.05b / Revenue TTM 121.28b)
Gross Margin = 73.66% ((Revenue TTM 121.28b - Cost of Revenue TTM 31.95b) / Revenue TTM)
Tobins Q-Ratio = 5.39 (Enterprise Value 232.02b / Book Value Of Equity 43.09b)
Interest Expense / Debt = 2.05% (Interest Expense 623.0m / Debt 30.39b)
Taxrate = 22.10% (from yearly Income Tax Expense: 2.61b / 11.79b)
NOPAT = 14.36b (EBIT 18.43b * (1 - 22.10%))
Current Ratio = 1.29 (Total Current Assets 35.70b / Total Current Liabilities 27.58b)
Debt / Equity = 1.06 (Debt 30.39b / last Quarter total Stockholder Equity 28.68b)
Debt / EBITDA = 1.29 (Net Debt 29.38b / EBITDA 23.58b)
Debt / FCF = 1.43 (Debt 30.39b / FCF TTM 21.30b)
Total Stockholder Equity = 29.68b (last 4 quarters mean)
RoA = 21.16% (Net Income 20.05b, Total Assets 94.77b )
RoE = 67.56% (Net Income TTM 20.05b / Total Stockholder Equity 29.68b)
RoCE = 32.83% (Ebit 18.43b / (Equity 29.68b + L.T.Debt 26.46b))
RoIC = 22.87% (NOPAT 14.36b / Invested Capital 62.78b)
WACC = 6.45% (E(209.18b)/V(239.58b) * Re(7.15%)) + (D(30.39b)/V(239.58b) * Rd(2.05%) * (1-Tc(0.22)))
Shares Correlation 5-Years: -70.0 | Cagr: -1.83%
Discount Rate = 7.15% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.11% ; FCFE base≈19.10b ; Y1≈23.03b ; Y5≈37.27b
Fair Price DCF = 5964 (DCF Value 636.30b / Shares Outstanding 106.7m; 5y FCF grow 21.96% → 3.0% )
Revenue Correlation: 16.08 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: 23.25
EPS Correlation: -19.09 | EPS CAGR: 63.34%
EPS Growth-of-Growth: 117.0